ストックスクリーナーアプリを入手
27.41
3.89%
0.96
前日終値:
$26.45
開ける：
$26.49
24時間の取引高:
709.74K
Relative Volume:
0.98
時価総額：
$1.73B
収益：
$10.00M
当期純損益:
$-425.15M
株価収益率:
-3.0133
EPS:
-9.0964
ネットキャッシュフロー:
$-210.48M
1週間 パフォーマンス:
+8.27%
1か月 パフォーマンス:
+57.30%
6か月 パフォーマンス:
+66.44%
1年 パフォーマンス:
+180.69%
1日の値動き範囲:
$25.88
$27.75
1週間の範囲:
$25.48
$29.25
52週間の値動き範囲:
$9.85
$44.60
Zenas Biopharma Inc Stock (ZBIO) Company Profile
名前
Zenas Biopharma Inc
セクター
電話
857-271-2954
住所
852 WINTER STREET, SUITE 250, WALTHAM
Compare ZBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ZBIO
Zenas Biopharma Inc
|
27.42 | 1.67B | 10.00M | -425.15M | -210.48M | -9.0964 |
VRTX
Vertex Pharmaceuticals Inc
|
522.15 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
673.64 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
917.18 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.58 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.72 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Zenas Biopharma Inc Stock (ZBIO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-05 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-03-20 | 開始されました | Wedbush | Outperform |
| 2025-02-04 | 開始されました | Wolfe Research | Outperform |
| 2024-12-16 | 開始されました | H.C. Wainwright | Buy |
| 2024-11-05 | 開始されました | Rodman & Renshaw | Buy |
| 2024-10-08 | 開始されました | Citigroup | Buy |
| 2024-10-08 | 開始されました | Guggenheim | Buy |
| 2024-10-08 | 開始されました | Jefferies | Buy |
| 2024-10-08 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Zenas Biopharma Inc (ZBIO) 最新ニュース
ZBIOZenas Biopharma Inc Earnings - Finviz
Zenas Wins Dismissal Of IPO Suit Over R&D Spending Claims - Law360
Zenas BioPharma Shakes IPO Investor’s Cash Burn Rate Lawsuit - Bloomberg Law News
Zenas BioPharma, Inc.(NasdaqGS: ZBIO) added to Russell 2500 Growth Benchmark - marketscreener.com
Zenas BioPharma, Inc.(NasdaqGS:ZBIO) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Zenas BioPharma, Inc.(NasdaqGS: ZBIO) dropped from Russell 2000 Value Benchmark - marketscreener.com
Zenas BioPharma, Inc.(NasdaqGS: ZBIO) added to Russell 2000 Growth Benchmark - marketscreener.com
Zenas BioPharma, Inc.(NasdaqGS: ZBIO) added to Russell 3000E Growth Benchmark - marketscreener.com
Does Zenas BioPharma (ZBIO) Shifting Into Russell Growth Indices Recast Its Core Investment Story? - simplywall.st
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Zenas BioPharma, Inc. (ZBIO) Investigation: Bronstein, Gewirtz - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
Join Class Action to Recover Losses from Zenas BioPharma, Inc. (Z - The National Law Review
ZBIO SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Investor Alert: Deadline Approaching to Join Zenas BioPharma, Inc. (ZBIO) Class ActionContact Levi & Korsinsky - The National Law Review
Levi & Korsinsky Notifies Zenas BioPharma, Inc. (ZBIO) Investors - The National Law Review
H.C. Wainwright Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $44 - Moomoo
ZBIO DEADLINE NOTICE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Zenas BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important June 16 Deadline in Securities Class Action First Filed by the Firm - TMX Newsfile
Zenas BioPharma, Inc. Actuals & Estimates (NASDAQ:ZBIO) - TradingView
Enterprise value to EBITDA forward of Zenas BioPharma, Inc. – BOATS:ZBIO - TradingView
Enterprise value to revenue forward of Zenas BioPharma, Inc. – NASDAQ:ZBIO - TradingView
ZBIO Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Zenas BioPharma, Inc. – BOATS:ZBIO - TradingView
Price to book forward of Zenas BioPharma, Inc. – BOATS:ZBIO - TradingView
Zenas Biopharma Inc (ZBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Zenas Biopharma Inc (ZBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction. - The Motley Fool
Zenas Biopharma Inc (ZBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Zenas Biopharma Inc (ZBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Zenas Biopharma Inc (ZBIO) Institutional Confidence - TradingKey
Zenas Biopharma Inc (ZBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Zenas Biopharma Inc (ZBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Director at Zenas BioPharma (ZBIO) receives 18,500 stock options at $18.71 strike - Stock Titan
Zenas BioPharma (ZBIO) director awarded 500K stock options at $18.71 - Stock Titan
Zenas BioPharma (ZBIO) director awarded 18,500 stock options at $18.71 - Stock Titan
Zenas BioPharma (ZBIO) awards 18,500 stock options to director Orloff - Stock Titan
Zenas BioPharma (ZBIO) awards 150,000 stock options to officer - Stock Titan
Director at Zenas BioPharma (ZBIO) receives 18,500 stock options grant - Stock Titan
Zenas BioPharma (ZBIO) director awarded 18,500 options at $18.71 - Stock Titan
Zenas BioPharma (ZBIO) awards stock options and ESPP shares to officer - Stock Titan
Zenas BioPharma (ZBIO) awards options and ESPP shares to officer - Stock Titan
Zenas Biopharma Inc (ZBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Zenas Biopharma Inc (ZBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView
ZBIO: Obexelimab nears launch for IgG4-RD, with a robust neuro-immunology pipeline advancing - TradingView
Zenas BioPharma (ZBIO) Is Up 13.3% After Strong Obexelimab Phase 3 Data And FDA BLA Filing - Sahm
Why is Zenas BioPharma stock rallying 9% today? By Investing.com - Investing.com Canada
Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit - The Manila Times
Zenas BioPharma (ZBIO) Revenue BreakdownMain Composition - Moomoo
Guggenheim Maintains Zenas BioPharma(ZBIO.US) With Buy Rating, Maintains Target Price $55 - Moomoo
Zenas Biopharma Inc (ZBIO) 財務データ
収益
当期純利益
現金流量
EPS
Zenas Biopharma Inc (ZBIO) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| MOULDER LEON O JR | Chief Executive Officer |
Apr 29 '26 |
Buy |
17.62 |
35,000 |
616,700 |
1,786,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Apr 28 '26 |
Buy |
18.02 |
25,000 |
450,500 |
1,751,039 |
| Lu Hongbo | Director |
Mar 31 '26 |
Buy |
18.63 |
3,768 |
70,198 |
426,736 |
| Fairmount Funds Management LLC | Director |
Mar 31 '26 |
Buy |
20.00 |
150,000 |
3,000,000 |
2,359,025 |
| MOULDER LEON O JR | Chief Executive Officer |
Mar 31 '26 |
Buy |
19.31 |
34,000 |
656,540 |
1,726,039 |
| MOULDER LEON O JR | Chief Executive Officer |
Mar 30 '26 |
Buy |
18.23 |
20,000 |
364,600 |
1,692,039 |
| Lu Hongbo | Director |
Mar 31 '26 |
Buy |
20.00 |
75,000 |
1,500,000 |
422,968 |
| Lu Hongbo | Director |
Feb 11 '26 |
Buy |
22.50 |
25,985 |
584,662 |
347,968 |
| Allen Patricia L | Director |
Feb 12 '26 |
Buy |
24.85 |
15,700 |
390,088 |
15,700 |
| Allen Patricia L | Director |
Feb 13 '26 |
Buy |
26.36 |
4,160 |
109,658 |
19,860 |
1.21%
3.14%
大文字化:
|
ボリューム (24 時間):